{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:56:16Z","timestamp":1791572176940,"version":"4.3.4"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT\u20101, SURMOUNT\u20102, and SURMOUNT\u20103.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In participants (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20094056) treated with tirzepatide (5\/10\/15\u2009mg or maximum tolerated dose 10\/15\u2009mg) versus placebo, depressive symptoms and suicidal ideation and behavior (SI\/SB) were measured using the Patient Health Questionnaire\u20109 (PHQ\u20109) and Columbia\u2010Suicide Severity Rating Scale (C\u2010SSRS), respectively. Nervous system and psychiatric disorder adverse events (AEs) were collected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean (SD) baseline PHQ\u20109 scores were 2.7 (3.0) for tirzepatide and 2.6 (3.1) for placebo, indicating no\/minimal symptoms of depression. At week 72, scores were 1.9 (2.7) and 2.4 (3.3), respectively (estimated treatment difference [SE]: \u22120.6 [0.1]);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001. Tirzepatide\u2010treated participants were less likely to shift to a more severe PHQ\u20109 category (18.2% vs. 24.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Using the C\u2010SSRS, 0.6% of participants in each group reported SI, most of which was considered low risk. SB (nonfatal) occurred in 0.1% of tirzepatide\u2010treated participants versus none with placebo. AEs were generally similar across groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this post hoc analysis, tirzepatide versus placebo did not appear to be associated with an increased risk of depression in participants with overweight\/obesity and without known major psychopathology. Rates of SI\/SB observed with tirzepatide were similar to those of other incretin\u2010based therapies. Further study of tirzepatide's safety in persons with significant psychiatric illness may be warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifiers: NCT04184622, NCT04657003, and NCT04657016\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.70122","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:19:12Z","timestamp":1768472352000},"page":"565-578","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of\n                    <scp>SURMOUNT<\/scp>"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-4609","authenticated-orcid":false,"given":"Thomas A.","family":"Wadden","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-5082","authenticated-orcid":false,"given":"Maria A.","family":"Oquendo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-3705","authenticated-orcid":false,"given":"Robert F.","family":"Kushner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-9037","authenticated-orcid":false,"given":"Dachuang","family":"Cao","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0614-8264","authenticated-orcid":false,"given":"Chrisanthi A.","family":"Karanikas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-742X","authenticated-orcid":false,"given":"Afton","family":"Kechter","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_3_1","unstructured":"Wegovy (Semaglutide) Injection Prescribing Information Novo Nordisk accessed February 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215256s005lbl.pdf."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_5_1","unstructured":"Zepbound (Tirzepatide) Injection Prescribing Information accessed February 2025 Eli Lilly and Company https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1710"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-023-00534-z"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23335"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23385"},{"key":"e_1_2_9_19_1","unstructured":"US Food and Drug Administration Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity accessed February 2025 https:\/\/www.fda.gov\/media\/175358\/download."},{"key":"e_1_2_9_20_1","unstructured":"European Medicines Agency Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201011 April 2024 accessed February 2025 https:\/\/www.ema.europa.eu\/en\/news\/meeting\u2010highlights\u2010pharmacovigilance\u2010risk\u2010assessment\u2010committee\u2010prac\u20108\u201011\u2010april\u20102024."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-031124-101146"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg275"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12935"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21187"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0800-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0017-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00431"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2011.13.1\/rshelton"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4346"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_2_9_35_1","unstructured":"Columbia Lighthouse Project The Columbia Protocol (C\u2010SSRS) accessed March 25 2025 https:\/\/cssrs.columbia.edu\/the\u2010columbia\u2010scale\u2010c\u2010ssrs\/about\u2010the\u2010scale\/."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.7.824"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.02.477"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss7101a1"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2022.03.008"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12963"},{"key":"e_1_2_9_42_1","unstructured":"Saxenda (Liraglutide Injection) Prescribing Information Novo Nordisk accessed March 2025 https:\/\/www.novo\u2010pi.com\/saxenda.pdf."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.12.017"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24067"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0091"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23946"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.765446"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103029"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:01:58Z","timestamp":1772967718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/oby.70122"],"URL":"https:\/\/doi.org\/10.1002\/oby.70122","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}